Premium
Paraganglioma of the head and neck region, treated with radiation therapy, a Rare Cancer Network study
Author(s) -
LassenRamshad Yasmin,
Ozyar Enis,
Alanyali Senem,
Poortmans Philip,
Houtte Paul,
Sohawon Schoeb,
Esassolak Mustafa,
Krengli Marco,
Villa Salvador,
Miller Robert,
Demiroz Candan,
Akyurek Serap,
AggerholmPedersen Ninna,
Thariat Juliette
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25611
Subject(s) - medicine , toxicity , radiation therapy , head and neck cancer , head and neck , stereotactic radiation therapy , surgery , cancer , paraganglioma , disease , radiology , stereotactic radiotherapy , radiosurgery , oncology
Background Paraganglioma of the head and neck (HNPGL) are rare often benign tumors. Surgery and radiation therapy (RT) are the main treatment choices. We present an analysis of outcome and toxicity after RT from 13 institutions of the Rare Cancer Network. Methods Data were collected using a questionnaire concerning patients' characteristics, treatment, and outcome. A total of 81 patients with 82 HNPGL were analyzed. Results The median follow‐up was 48 months (1‐456). Sixty‐two lesions were treated with conventional RT and 20 lesions with stereotactic RT. Local control (LC) was achieved in 69 out of 77 lesions. Late toxicity occurred in 17 patients. Patients treated with stereotactic RT experienced neither disease progression nor late toxicity. Four patients with a follow‐up longer than 20 years experienced disease progression. Conclusion RT for HNPGL offered good local control with acceptable toxicity. Stereotactic RT might offer better results. Long‐term follow‐up is required.